Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,268
Out of 5,072 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $42.54 | -1.27% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $147.50 | +154.24% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $78.21 | +47.04% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $79.66 | +15.49% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $13.33 | -9.98% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.97 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $69.00 | +30.43% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $267.79 | +0.83% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $104.35 | -34.83% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $11.97 | +275.94% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $114.70 | +139.76% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $26.21 | +41.17% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $61.69 | -2.74% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $101.36 | -65.47% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $328.82 | -75.37% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $42.54
Upside: -1.27%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $147.50
Upside: +154.24%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $78.21
Upside: +47.04%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $79.66
Upside: +15.49%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $13.33
Upside: -9.98%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.97
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $69.00
Upside: +30.43%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $267.79
Upside: +0.83%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $104.35
Upside: -34.83%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $11.97
Upside: +275.94%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $114.70
Upside: +139.76%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $26.21
Upside: +41.17%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $61.69
Upside: -2.74%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $101.36
Upside: -65.47%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $328.82
Upside: -75.37%